Plakar raises $3M from Seedcamp to Launch AI-Ready Open Source Backup Platform
PARIS--(BUSINESS WIRE)--Plakar, an open-source backup and restore platform, today announced the general availability of its first stable release, alongside a $3 million pre-seed funding round led by Seedcamp. The round includes participation from leading venture firms HelloWorld, IrregularExpression, Galion.exe, Kima Ventures, OPRTRS and renowned angel investors, including Olivier Pomel (Datadog), Solomon Hykes (Docker), and Alexandre Yazdi (Voodoo).
'With Plakar, we're providing an open‑source solution that simplifies backup and restore processes while making enterprise‑grade data resilience accessible to businesses of all sizes,' said Julien Mangeard, co-founder and CEO of Plakar.
Plakar's modern architecture enables users to protect and orchestrate various types of data across a diverse set of environments in a way that is fast, reliable, and resource-efficient. Plakar doesn't just store files—it preserves complete application and AI-pipeline context. It deduplicates and compresses data inline, encrypts it end-to-end, and organizes it into a structured, queryable repository.
Unlike traditional backup solutions, where data becomes a dormant cost, Plakar transforms backup storage into an active, valuable resource. Its architecture enables seamless reuse of protected data for production workflows, such as AI model training, data analytics, compliance auditing, or offloading intensive tasks from production systems, unlocking new operational efficiencies and accelerating innovation.
'With Plakar, we're providing an open-source solution that simplifies backup and restore processes while making enterprise-grade data resilience accessible to businesses of all sizes,' said Julien Mangeard, co-founder and CEO of Plakar. 'This product launch and funding announcement is a significant milestone, and we are thrilled to begin this journey with the support of such renowned partners and investors.'
'In an era where AI systems are generating and processing unprecedented volumes of data, ensuring the integrity and security of that data is paramount,' said Sia Houchangnia, Partner at Seedcamp. 'Plakar's approach of combining open-source flexibility with enterprise-grade features aligns with our belief in empowering developers and businesses with accessible, reliable, and efficient tools.'
Plakar's engine, called Kloset, turns each backup into a compact, self-contained, immutable data unit that travels with its own structure, metadata, and encryption. Like a container for data, it removes the need for external coordination or dependencies—enabling fast, secure, and portable backups across any environment, from local files to distributed cloud systems.
Plakar's end-to-end workflow keeps every backup lean, secure, and instantly recoverable with the following features:
Data Collection: Immutable, content-addressed snapshots capture incremental versions of datasets and model checkpoints so experiments remain fully reproducible while slashing redundant storage by up to 90%.
Data Visualization: Snapshots are browsable and verifiable without restoring, and restores are precise and fast.
Data Security: Plakar uses the same end-to-end encryption to ensure compliance with stringent data-protection regulations.
Resource Efficiency: By combining advanced deduplication and compression techniques, Plakar minimizes storage requirements, allowing for more restore points with less space.
Interoperability: Plakar integrates seamlessly with various storage environments, including cloud-based storage, S3-compatible solutions, local servers, NAS, SAN, tape drives, and Kubernetes volumes.
With the new funding, Plakar plans to expand its engineering team to accelerate feature development and enhance platform scalability. Additionally, the company aims to grow its customer base by targeting AI-focused startups and enterprises seeking efficient, secure, and reproducible data management solutions.
To learn more about Plakar and its vision for the future of data backups, read the stable release announcement blog post.
About Plakar
Plakar is an open-source backup and restore solution designed to simplify data protection for businesses of all sizes. Plakar protects anything—from local files to multi-cloud AI pipelines—while keeping every snapshot lean, encrypted, and instantly recoverable. Headquartered in Paris, Plakar is on a mission to give every organisation the freedom to backup any data, anywhere. Learn more at plakar.io.
About Seedcamp
Seedcamp partners with Europe's most exceptional tech founders from Day One. Across their company-building journeys, founders and their teams get access to an unparalleled network, unfiltered advice, and unwavering support.
With almost two decades at the heart of Europe's tech ecosystem, Seedcamp has earned a reputation for identifying and nurturing the continent's most promising entrepreneurs with the grit and vision to reshape the future. The Seedcamp Nation now stands at 500+ strong and includes publicly listed UiPath and Wise, unicorns Revolut, Synthesia, Sorare, Pleo, wefox, and viz.ai, and a stable of fast-growing businesses across various sectors, such as Sylvera, Lindus Health, Yonder, 9fin and Maze.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, announced today that it will present data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) in an oral presentation at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 25-27, 2025, in Anaheim, California. SAPPHIRE evaluated the safety and efficacy of apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for people living with SMA who are receiving SMN-targeted treatments. Scholar Rock previously shared positive topline data from the trial in October 2024 and announced in March 2025 that the U.S. FDA accepted its BLA for apitegromab. The application has a priority review designation, and the FDA has assigned a PDUFA target action date of September 22, 2025. Details of the oral presentation are as follows: Title: Efficacy and Safety of Apitegromab in Individuals with Type 2 and Type 3 Spinal Muscular Atrophy Evaluated in the Phase 3 SAPPHIRE Trial Presentation type: Oral presentation Presenter: Basil T. Darras, M.D., Associate Neurologist-in-Chief, Boston Children's Hospital and Professor of Neurology, Harvard Medical School Location: Sequoia Ballroom, Disney's Grand Californian Hotel Date and time: Friday, June 27, 11:20 a.m. PDT Scholar Rock will also present a poster on a systematic literature review of characterization of the longer-term effectiveness of SMN-targeted therapies for SMA. The details of that poster presentation are as follows: Title: Characterization of the Longer-Term Effectiveness of SMN-Targeted Treatments for Spinal Muscular Atrophy: A Systematic Literature Review Presentation type: Poster presentation Presenter: Jena M. Krueger, M.D., Helen DeVos Children's Hospital Grand Rapids, Michigan Location: Frontier Tower Magic Kingdom Rooms 2 & 3, Disneyland Hotel Date and time: Wednesday, June 25, 4:30-6:30 p.m. PDT The presentations will be made available in the Publications & Posters section of Scholar Rock's website following the conference. For conference information, visit About Apitegromab Apitegromab is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is the first muscle-targeted treatment candidate in spinal muscular atrophy (SMA) to demonstrate clinical success in a pivotal phase 3 clinical trial. Additionally, in the EMBRAZE Phase 2 proof-of-concept trial in obesity, patients receiving apitegromab dosed at 10mg/kg with tirzepatide over 24 weeks showed a statistically significant preservation of lean mass relative to tirzepatide alone. Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that its highly selective targeting of pro- and latent forms of myostatin with apitegromab may lead to a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. Apitegromab has not been approved for any use by the FDA or any other regulatory agency. About the Phase 3 SAPPHIRE Trial SAPPHIRE was a randomized, double-blind, placebo-controlled Phase 3 clinical trial that evaluated the safety and efficacy of apitegromab in nonambulatory patients with Types 2 and 3 SMA who were receiving current standard of care (either nusinersen or risdiplam). SAPPHIRE enrolled 156 patients aged 2-12 years old in the main efficacy population. These patients were randomized 1:1:1 to receive either apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo by intravenous (IV) infusion every 4 weeks for 12 months. An exploratory population including 32 patients aged 13-21 years old was also evaluated. These patients were randomized 2:1 to receive either apitegromab 20 mg/kg or placebo every 4 weeks for 12 months. The SAPPHIRE trial met its primary endpoint for the main efficacy population with a statistically significant 1.8-point improvement (p=0.0192) based on apitegromab combined dose (10 mg/kg and 20 mg/kg) and standard of care (SOC) versus placebo and SOC as measured by the Hammersmith Functional Motor Scale-Expanded at week 52 (additional details in the topline data release). About SMA Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disease that afflicts an estimated 30,000 to 35,000 people in the United States and Europe. The disease is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk, and progressive muscle weakness. While there has been progress in the development of therapeutics that address the loss of motor neurons, there continues to be a high unmet need for therapies that directly address the progressive muscle weakness that leads to loss of motor function in SMA. About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, progress and plans for apitegromab. The use of words such as 'may,' 'might,' 'could,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether the results from the Phase 3 clinical trial of apitegromab, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates, and may not be sufficient for regulatory approval; Scholar Rock's ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline; the data generated from Scholar Rock's nonclinical studies and clinical trials; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, supply for apitegromab; and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances; its ability to obtain regulatory approval of apitegromab; and the anticipated commercial launch in the United States of apitegromab in the fourth quarter of 2025 and new business initiatives; as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.
Business Wire
an hour ago
- Business Wire
Wiley Appoints Craig Albright as Executive Vice President and Chief Financial Officer
BUSINESS WIRE)--Wiley (NYSE: WLY), one of the world's largest publishers and a global leader in research and education, today announced the appointment of Craig Albright as executive vice president and chief financial officer, effective June 26, 2025. Chris Caridi, who has led Wiley's finance organization as interim chief financial officer, will continue with the role of senior vice president, chief accounting officer and finance transformation leader. Albright joins Wiley with over 30 years of global leadership expertise in finance, strategy, and consulting roles. He recently served as CFO, Americas and Global Cash Center Lead at Xerox, where he oversaw multiple business units with annual sales ranging from $100 million to $2 billion, drove portfolio decisions, delivered significant cost savings, and instituted programs to improve cash conversion. Prior to that, he served as CFO, Commercial Excellence of Xerox overseeing strategic finance activities for three product divisions, including reporting, performance management, FP&A and capital allocation. He developed an organic growth program that identified strategic opportunities and performance indicators, resulting in $300 million in new revenue. In addition, Albright has successfully led finance organizations through global economic crises and disruptions while driving organic and inorganic growth and consolidating enterprise systems. Wiley recently reported its Fiscal 2025 earnings, where it delivered growth in all key metrics, including revenue, margins, and free cash flow. 'Craig joins Wiley at an exciting time for the Company. We are meeting and exceeding our financial commitments, driving growth in our core business while delivering material margin expansion, and capitalizing on emerging market opportunities in the corporate sector through AI licensing, data analytics, and knowledge services. Craig's exceptional track record of driving high-quality growth globally through disciplined investment and innovation, cost synergies, and operating efficiency lines up perfectly with our strategic objectives,' said Matthew Kissner, president and CEO of Wiley. 'I am very impressed with Craig's financial acumen, resiliency and determination, as evidenced by his extensive roles throughout multiple leadership changes at Xerox. I look forward to partnering with Craig as we generate significant value for our customers, partners, and shareholders.' 'Joining Wiley represents an incredible opportunity to further position the Company for the AI age,' said Craig Albright, incoming executive vice president and chief financial officer. 'The Company's strong core business, coupled with its clear strategic priorities, creates multiple pathways for value creation. I'm eager to work with Matt, the talented Finance team, and all my new colleagues to build on the momentum that is driving margin and cash flow expansion, continuing to build core business momentum, and capitalizing on emerging opportunities for Wiley's high-quality content, data, and knowledge services.' 'On behalf of the Board, the Executive Leadership Team, and all our colleagues, I want to express my deep gratitude to Chris Caridi for his leadership and to our entire Finance team for their resilience, focus, and strong performance through this transition,' added Kissner. About Wiley Wiley (NYSE: WLY) is one of the world's largest publishers and a trusted leader in research and learning. Our industry-leading content, services, platforms, and knowledge networks are tailored to meet the evolving needs of our customers and partners, including researchers, students, instructors, professionals, institutions, and corporations. We empower knowledge-seekers to transform today's biggest obstacles into tomorrow's brightest opportunities. For more than two centuries, Wiley has been delivering on its timeless mission to unlock human potential. Visit us at Follow us on Facebook, Twitter, LinkedIn and Instagram.
Business Wire
an hour ago
- Business Wire
Ancora Heart Inc. Reaches First Enrollment Milestone in CORCINCH-HF Heart Failure Pivotal Trial
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Ancora Heart, Inc., a medical device company developing a transcatheter device-based therapy to address heart failure (HF), today announced that it has reached the first enrollment milestone in the CORCINCH-HF pivotal trial evaluating the AccuCinch ® Transcatheter Left Ventricular Restoration System in patients with heart failure with reduced ejection fraction (HFrEF). Six-month follow-up data on these 250 patients will support the company's Premarket Approval (PMA) submission to the U.S. Food and Drug Administration (FDA). 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle. Reaching this milestone is an incredible accomplishment in heart failure research." - Jeff Closs, president and CEO, Ancora Heart Share The AccuCinch System is an investigational device designed to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. Results from early clinical studies were presented at the 2023 Technology and Heart Failure Therapeutics conference and simultaneously published in the Journal of Cardiac Failure. The AccuCinch System was granted Breakthrough Device Designation from the FDA in 2022. 'The AccuCinch System is the only completely transcatheter procedure to treat the enlarged left ventricle,' said Jeff Closs, president and CEO of Ancora Heart. 'Reaching this milestone is an incredible accomplishment in heart failure research and a model example of collaboration across heart failure and structural heart care teams at participating CORCINCH-HF clinical trial sites. We'd like to thank study investigators for their commitment to innovation and partnership, and we look forward to building on this momentum as we work toward reaching our full enrollment target of 400 patients.' The CORCINCH-HF study is evaluating the safety and effectiveness of the AccuCinch System in patients who have symptomatic HF with reduced ejection fraction. An estimated 6.7 million adults in the U.S. live with heart failure, and about half have HFrEF. 1,2 'Despite advances in guideline-directed medical therapy, many patients with heart failure continue to experience debilitating symptoms,' said Ulrich Jorde, MD, global co-principal investigator of the CORCINCH-HF Study, professor of medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York. 'Reaching this milestone in the CORCINCH-HF study is a significant step toward determining whether this treatment option may improve the length and quality of their lives.' 'AccuCinch is a device-based therapy aimed at reverse remodeling of the enlarged left ventricle,' said Mark Reisman, MD*, global co-principal investigator of the CORCINCH-HF Study, director of structural heart disease at NewYork-Presbyterian/Weill Cornell Medical Center and co-director of structural heart disease for NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital, who was recruited to Weill Cornell Medicine as a professor of medicine. 'This trial is designed to evaluate the safety of the device and procedure and whether we can improve heart structure and function and thereby help patients feel better, avoid hospitalizations and live longer.' About Heart Failure An estimated 6.7 million adults in the U.S. live with heart failure, a condition in which the heart's muscles weaken and lose their ability to pump enough oxygen-rich blood to the body. 1,2 Heart failure patients suffer from debilitating symptoms, including persistent exhaustion, trouble breathing and confusion, as well as frequent hospitalizations. About half of HF patients have heart failure with a reduced ejection fraction (HFrEF) and an enlarged left ventricle, the main pumping chamber of the heart, which causes more stress on the heart and leads to reduced pumping efficiency. Up to 50% of people who develop heart failure die within five years of diagnosis. 3 About the AccuCinch ® Transcatheter Left Ventricular Restoration System The AccuCinch System is an investigational device designed to augment the existing care cardiologists provide their heart failure patients. For patients in whom HF has progressed beyond the ability of medications and pacemakers to manage symptoms, the AccuCinch System may provide a new treatment option to fill the gap between medication or pacemaker therapy and left ventricular assist devices (LVADs) or a heart transplant. During the minimally invasive AccuCinch System procedure, a flexible implant is attached to the inner wall of the left ventricle and then cinched. The implant is intended to reduce the size of the left ventricle, reduce ventricular wall stress, and support and strengthen the heart wall. The AccuCinch System is under clinical evaluation to determine its potential benefits related to patient symptoms, quality of life and life expectancy. About the CORCINCH-HF Study The CORCINCH-HF Study (NCT04331769) is a prospective, randomized, open-label, multicenter, international, clinical safety and effectiveness investigation of the AccuCinch Transcatheter Left Ventricular Restoration System, which is designed to enroll 400 patients at centers worldwide. The study has a unique design allowing initial analysis of safety and clinical effectiveness for PMA submission after the first 250 patients have reached six months of follow-up, and then a second analysis after the entire cohort has reached 12 months of follow-up. About Ancora Heart, Inc. Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company's lead product is the AccuCinch ® Transcatheter Left Ventricular Restoration System, an investigational device currently being studied in the CORCINCH-HF pivotal trial. Ancora Heart is a privately held company located in Santa Clara, Calif. For more information, about Ancora Heart and its products, visit and follow the company on Facebook, LinkedIn and X. * Dr. Reisman reports travel support from Ancora Heart. 1 Martin SS, Aday AW, Almarzooq ZI, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee; Stroke Statistics Subcommittee. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024;149:e347–913. 2 Murphy S, Ibrahim N, Januzzi J. Heart Failure with Reduced Ejection Fraction, A Review. JAMA. 2020;324(5):488-504 3 Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-596.
